The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - My name is associated with a few patents from inventions as part of my employment at Genentech
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Russell Petry
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Chang Xu
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Pending patent
 
Ryon Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
David Fabrizio
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - 1. Novel PD-L1 binding polypeptides for imaging 2. Methods and systems for evaluating tumor mutational burden 3. Therapeutic and diagnostic methods for cancer 4. Targeted therapeutics based on engineered proteins for tyrosine kinase receptors, including
 
Jie He
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Foundation Medicine
 
Ole Gjoerup
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Foundation Medicine
 
Lincoln Pasquina
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Foundation Medicine
 
Zoe June Assaf
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche; Immunocore
Research Funding - Genentech/Roche
Travel, Accommodations, Expenses - Genentech
 
Kobe Yuen
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
 
Matthew J. Wongchenko
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Pratyush Gupta
Employment - CellMax Life; Genentech
Stock and Other Ownership Interests - CellMax Life; Genentech
Research Funding - CellMax Life
Patents, Royalties, Other Intellectual Property - Patent(s) in progress
Travel, Accommodations, Expenses - CellMax Life; Genentech
 
Sanjeev Mariathasan
No Relationships to Disclose
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche